TY - JOUR
T1 - Long-term outcomes after transcatheter aortic valve implantation from a single high-volume center (The Milan Experience)
AU - Ruparelia, Neil
AU - Latib, Azeem
AU - Buzzatti, Nicola
AU - Giannini, Francesco
AU - Figini, Filippo
AU - Mangieri, Antonio
AU - Regazzoli, Damiano
AU - Stella, Stefano
AU - Sticchi, Alessandro
AU - Kawamoto, Hiroyoshi
AU - Tanaka, Akihito
AU - Agricola, Eustachio
AU - Monaco, Fabrizio
AU - Castiglioni, Alessandro
AU - Ancona, Marco
AU - Cioni, Micaela
AU - Spagnolo, Pietro
AU - Chieffo, Alaide
AU - Montorfano, Matteo
AU - Alfieri, Ottavio
AU - Colombo, Antonio
PY - 2016/3/1
Y1 - 2016/3/1
N2 - Transcatheter aortic valve implantation (TAVI) is now the treatment of choice for patients with symptomatic aortic stenosis who are inoperable or with high surgical risk. Data with regards to contemporary clinical practice and long-term outcomes are sparse. To evaluate temporal changes in TAVI practice and explore procedural and long-term clinical outcomes of patients in a contemporary "real-world" population, outcomes of 829 patients treated from November 2007 to May 2015, at the San Raffaele Scientific Institute, Milan, Italy, were retrospectively analyzed. Median follow-up was 568 days, with the longest follow-up of 2,677 days. Overall inhospital mortality was 3.5%. During the study period, there was a trend toward treating younger, lower risk patients. Overall mortality rates were 3.5% (30 days), 14% (1 year), 22% (2 years), 29% (3 years), 37% (4 years), 47% (5 years), 53% (6 years), and 72% (7 years). The survival probability at 5 years was significantly higher in patients treated through the transfemoral (TF) route compared to other vascular access sites (log rank p
AB - Transcatheter aortic valve implantation (TAVI) is now the treatment of choice for patients with symptomatic aortic stenosis who are inoperable or with high surgical risk. Data with regards to contemporary clinical practice and long-term outcomes are sparse. To evaluate temporal changes in TAVI practice and explore procedural and long-term clinical outcomes of patients in a contemporary "real-world" population, outcomes of 829 patients treated from November 2007 to May 2015, at the San Raffaele Scientific Institute, Milan, Italy, were retrospectively analyzed. Median follow-up was 568 days, with the longest follow-up of 2,677 days. Overall inhospital mortality was 3.5%. During the study period, there was a trend toward treating younger, lower risk patients. Overall mortality rates were 3.5% (30 days), 14% (1 year), 22% (2 years), 29% (3 years), 37% (4 years), 47% (5 years), 53% (6 years), and 72% (7 years). The survival probability at 5 years was significantly higher in patients treated through the transfemoral (TF) route compared to other vascular access sites (log rank p
UR - http://www.scopus.com/inward/record.url?scp=84958920716&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84958920716&partnerID=8YFLogxK
U2 - 10.1016/j.amjcard.2015.12.014
DO - 10.1016/j.amjcard.2015.12.014
M3 - Article
C2 - 26742477
AN - SCOPUS:84958920716
SN - 0002-9149
VL - 117
SP - 813
EP - 819
JO - American Journal of Cardiology
JF - American Journal of Cardiology
IS - 5
ER -